Human T-cell leukemia virus type-I Tax induces the expression of CD83 on T cells

Retrovirology

Masataka Nakamura⁵  Aftab A Ansari¹  Takeaki Tomoyose²  Takuya Fukushima³  Reiko Tanaka⁴  Hideki Fujii⁴  Yoshiaki Takahashi⁴  Mariko Mizuguchi⁵  Yuetsu Tanaka⁴ 

[1] Department of Pathology, Emory University School of Medicine, Atlanta, GA, USA;Division of Endocrinology, Diabetes and Metabolism, Haematology, Rheumatology (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan;Laboratory of Hematoimmunology, School of Health Sciences, Faculty of Medicine, University of the Ryukyus, Okinawa, Japan;Department of Immunology, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara-cho, Okinawa 903-0215, Japan;Human Gene Sciences Center, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, Japan

关键词: PGE2;    ATL;    Tax;    HTLV;    CD83;   

Others  :  1221136
DOI  :  10.1186/s12977-015-0185-1

 received in 2015-04-23, accepted in 2015-06-21,  发布年份 2015

【 摘 要 】

Background

CD83, a cell surface glycoprotein that is stably expressed on mature dendritic cells, can be transiently induced on other hematopoietic cell lineages upon cell activation. In contrast to the membrane form of CD83, soluble CD83 appears to be immunosuppressive. In an analysis of the phenotype of leukemic CD4 ⁺T cells from patients with adult T-cell leukemia (ATL), we found that a number of primary CD4 ⁺T cells became positive for cell surface CD83 after short-term culture, and that most of these CD83 ⁺CD4 ⁺T cells were positive for human T-cell leukemia virus type-I (HTLV-I) Tax (Tax1). We hypothesized that Tax1 is involved in the induction of CD83.

Result

We found that CD83 was expressed selectively on Tax1-expressing human CD4 ⁺T cells in short-term cultured peripheral blood mononuclear cells (PBMCs) isolated from HTLV-I ⁺donors, including ATL patients and HTLV-I carriers. HTLV-I-infected T cell lines expressing Tax1 also expressed cell surface CD83 and released soluble CD83. CD83 can be expressed in the JPX-9 cell line by cadmium-mediated Tax1 induction and in Jurkat cells or PBMCs by Tax1 introduction via infection with a recombinant adenovirus carrying the Tax1 gene. The CD83 promoter was activated by Tax1 in an NF-κB-dependent manner. Based on a previous report showing soluble CD83-mediated prostaglandin E2 (PGE2) production from human monocytes in vitro, we tested if PGE2 affected HTLV-I propagation, and found that PGE2 strongly stimulated expression of Tax1 and viral structural molecules.

Conclusions

Our results suggest that HTLV-I induces CD83 expression on T cells via Tax1 -mediated NF-κB activation, which may promote HTLV-I infection in vivo.

【 授权许可】

   
2015 Tanaka et al.

【 图 表 】

Figure1.

Figure2.

Figure3.

Figure4.

Figure5.

Figure6.

Figure7.

Figure8.

Figure9.

Figure10.

【 参考文献 】

• [1]Zhou LJ, Schwarting R, Smith HM, Tedder TF. A novel cell-surface molecule expressed by human interdigitating reticulum cells, Langerhans cells, and activated lymphocytes is a new member of the Ig superfamily. J Immunol. 1992; 149:735-742.
• [2]Cao W, Lee SH, Lu J. CD83 is preformed inside monocytes, macrophages and dendritic cells, but it is only stably expressed on activated dendritic cells. Biochem J. 2005; 385:85-93.
• [3]Wolenski M, Cramer SO, Ehrlich S, Steeg C, Grossschupff G, Tenner-Racz K et al.. Expression of CD83 in the murine immune system. Med Microbiol Immunol. 2003; 192:189-192.
• [4]Prazma CM, Yazawa N, Fujimoto Y, Fujimoto M, Tedder TF. CD83 expression is a sensitive marker of activation required for B cell and CD4+ T cell longevity in vivo. J Immunol. 2007; 179:4550-4562.
• [5]Reinwald S, Wiethe C, Westendorf AM, Breloer M, Probst-Kepper M, Fleischer B et al.. CD83 expression in CD4+ T cells modulates inflammation and autoimmunity. J Immunol. 2008; 180:5890-5897.
• [6]Yamashiro S, Wang JM, Yang D, Gong WH, Kamohara H, Yoshimura T. Expression of CCR6 and CD83 by cytokine-activated human neutrophils. Blood. 2000; 96:3958-3963.
• [7]Mailliard RB, Alber SM, Shen H, Watkins SC, Kirkwood JM, Herberman RB et al.. IL-18-induced CD83+ CCR7+ NK helper cells. J Exp Med. 2005; 202:941-953.
• [8]Fujimoto Y, Tu L, Miller AS, Bock C, Fujimoto M, Doyle C et al.. CD83 expression influences CD4+ T cell development in the thymus. Cell. 2002; 108:755-767.
• [9]Hock BD, Kato M, McKenzie JL, Hart DN. A soluble form of CD83 is released from activated dendritic cells and B lymphocytes, and is detectable in normal human sera. Int Immunol. 2001; 13:959-967.
• [10]Aerts-Toegaert C, Heirman C, Tuyaerts S, Corthals J, Aerts JL, Bonehill A et al.. CD83 expression on dendritic cells and T cells: correlation with effective immune responses. Eur J Immunol. 2007; 37:686-695.
• [11]Lechmann M, Krooshoop DJ, Dudziak D, Kremmer E, Kuhnt C, Figdor CG et al.. The extracellular domain of CD83 inhibits dendritic cell-mediated T cell stimulation and binds to a ligand on dendritic cells. J Exp Med. 2001; 194:1813-1821.
• [12]Lin H, Liang S, Zhong Z, Wen J, Li W, Wang L et al.. Soluble CD83 inhibits human monocyte differentiation into dendritic cells in vitro. Cell Immunol. 2014; 292:25-31.
• [13]Hock BD, Fernyhough LJ, Gough SM, Steinkasserer A, Cox AG, McKenzie JL. Release and clinical significance of soluble CD83 in chronic lymphocytic leukemia. Leuk Res. 2009; 33:1089-1095.
• [14]Kreiser S, Eckhardt J, Kuhnt C, Stein M, Krzyzak L, Seitz C et al.. Murine CD83-positive T cells mediate suppressor functions in vitro and in vivo. Immunobiology. 2015; 220:270-279.
• [15]Chen L, Zhu Y, Zhang G, Gao C, Zhong W, Zhang X. CD83-stimulated monocytes suppress T-cell immune responses through production of prostaglandin E2. Proc Natl Acad Sci USA. 2011; 108:18778-18783.
• [16]Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita KI. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA. 1981; 78:6476-6480.
• [17]Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender A et al.. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet. 1985; 2:407-410.
• [18]Osame M, Matsumoto M, Usuku K, Izumo S, Ijichi N, Amitani H et al.. Chronic progressive myelopathy associated with elevated antibodies to human T-lymphotropic virus type I and adult T-cell leukemialike cells. Ann Neurol. 1987; 21:117-122.
• [19]Ishitsuka K, Tamura K. Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncol. 2014; 15:e517-e526.
• [20]Yoshida M. Molecular approach to human leukemia: isolation and characterization of the first human retrovirus HTLV-1 and its impact on tumorigenesis in adult T-cell leukemia. Proc Jpn Acad Ser B Phys Biol Sci. 2010; 86:117-130.
• [21]Romanelli MG, Diani E, Bergamo E, Casoli C, Ciminale V, Bex F et al.. Highlights on distinctive structural and functional properties of HTLV Tax proteins. Front Microbiol. 2013; 4:271.
• [22]Matsuoka M, Yasunaga J. Human T-cell leukemia virus type 1: replication, proliferation and propagation by Tax and HTLV-1 bZIP factor. Curr Opin Virol. 2013; 3:684-691.
• [23]Hinuma Y, Gotoh Y, Sugamura K, Nagata K, Goto T, Nakai M et al.. A retrovirus associated with human adult T-cell leukemia: in vitro activation. Gan. 1982; 73:341-344.
• [24]Gotoh YI, Sugamura K, Hinuma Y. Healthy carriers of a human retrovirus, adult T-cell leukemia virus (ATLV): demonstration by clonal culture of ATLV-carrying T cells from peripheral blood. Proc Natl Acad Sci USA. 1982; 79:4780-4782.
• [25]Bangham CR. CTL quality and the control of human retroviral infections. Eur J Immunol. 2009; 39:1700-1712.
• [26]Tanaka Y, Takahashi Y, Tanaka R, Kodama A, Fujii H, Hasegawa A et al.. Elimination of human T cell leukemia virus type-1-infected cells by neutralizing and antibody-dependent cellular cytotoxicity-inducing antibodies against human t cell leukemia virus type-1 envelope gp46. AIDS Res Hum Retroviruses. 2014; 30:542-552.
• [27]Murphy EL, Glynn SA, Fridey J, Smith JW, Sacher RA, Nass CC et al.. Increased incidence of infectious diseases during prospective follow-up of human T-lymphotropic virus type II- and I-infected blood donors. Retrovirus Epidemiology Donor Study. Arch Intern Med. 1999; 159:1485-1491.
• [28]Yamazato Y, Miyazato A, Kawakami K, Yara S, Kaneshima H, Saito A. High expression of p40(tax) and pro-inflammatory cytokines and chemokines in the lungs of human T-lymphotropic virus type 1-related bronchopulmonary disorders. Chest. 2003; 124:2283-2292.
• [29]Santos SB, Porto AF, Muniz AL, de Jesus AR, Magalhaes E, Melo A et al.. Exacerbated inflammatory cellular immune response characteristics of HAM/TSP is observed in a large proportion of HTLV-I asymptomatic carriers. BMC Infect Dis. 2004; 4:7. BioMed Central Full Text
• [30]Funai N, Shimamoto Y, Yoshida S, Nagai Y, Nakazato S, Kohashi O. Differences in immune functions between human T-lymphotropic virus type I carriers and patients with adult T-cell leukemia/lymphoma. Clin Immunol Immunopathol. 1996; 80:325-332.
• [31]Yasunaga J, Sakai T, Nosaka K, Etoh K, Tamiya S, Koga S et al.. Impaired production of naive T lymphocytes in human T-cell leukemia virus type I-infected individuals: its implications in the immunodeficient state. Blood. 2001; 97:3177-3183.
• [32]Nascimento CR, Lima MA, de Andrada Serpa MJ, Espindola O, Leite AC, Echevarria-Lima J. Monocytes from HTLV-1-infected patients are unable to fully mature into dendritic cells. Blood. 2011; 117:489-499.
• [33]Hock BD, Haring LF, Steinkasserer A, Taylor KG, Patton WN, McKenzie JL. The soluble form of CD83 is present at elevated levels in a number of hematological malignancies. Leuk Res. 2004; 28:237-241.
• [34]Higashimura N, Takasawa N, Tanaka Y, Nakamura M, Sugamura K. Induction of OX40, a receptor of gp34, on T cells by trans-acting transcriptional activator, Tax, of human T-cell leukemia virus type I. Jpn J Cancer Res. 1996; 87:227-231.
• [35]Kress AK, Grassmann R, Fleckenstein B. Cell surface markers in HTLV-1 pathogenesis. Viruses. 2011; 3:1439-1459.
• [36]Ohtani K, Tsujimoto A, Tsukahara T, Numata N, Miura S, Sugamura K et al.. Molecular mechanisms of promoter regulation of the gp34 gene that is trans-activated by an oncoprotein Tax of human T cell leukemia virus type I. J Biol Chem. 1998; 273:14119-14129.
• [37]Dudziak D, Kieser A, Dirmeier U, Nimmerjahn F, Berchtold S, Steinkasserer A et al.. Latent membrane protein 1 of Epstein-Barr virus induces CD83 by the NF-kappaB signaling pathway. J Virol. 2003; 77:8290-8298.
• [38]Mori N, Fujii M, Ikeda S, Yamada Y, Tomonaga M, Ballard DW et al.. Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells. Blood. 1999; 93:2360-2368.
• [39]Senechal B, Boruchov AM, Reagan JL, Hart DN, Young JW. Infection of mature monocyte-derived dendritic cells with human cytomegalovirus inhibits stimulation of T-cell proliferation via the release of soluble CD83. Blood. 2004; 103:4207-4215.
• [40]Kummer M, Turza NM, Muhl-Zurbes P, Lechmann M, Boutell C, Coffin RS et al.. Herpes simplex virus type 1 induces CD83 degradation in mature dendritic cells with immediate-early kinetics via the cellular proteasome. J Virol. 2007; 81:6326-6338.
• [41]Bates JM, Flanagan K, Mo L, Ota N, Ding J, Ho S et al.. Dendritic cell CD83 homotypic interactions regulate inflammation and promote mucosal homeostasis. Mucosal Immunol. 2015; 8:414-428.
• [42]Moriuchi M, Inoue H, Moriuchi H. Reciprocal interactions between human T-lymphotropic virus type 1 and prostaglandins: implications for viral transmission. J Virol. 2001; 75:192-198.
• [43]Dumais N, Pare ME, Mercier S, Bounou S, Marriot SJ, Barbeau B et al.. T-cell receptor/CD28 engagement when combined with prostaglandin E2 treatment leads to potent activation of human T-cell leukemia virus type 1. J Virol. 2003; 77:11170-11179.
• [44]Melamed A, Laydon DJ, Gillet NA, Tanaka Y, Taylor GP, Bangham CR. Genome-wide determinants of proviral targeting, clonal abundance and expression in natural HTLV-1 infection. PLoS Pathog. 2013; 9:e1003271.
• [45]Tanaka Y, Tozawa H, Koyanagi Y, Shida H. Recognition of human T cell leukemia virus type I (HTLV-I) gag and pX gene products by MHC-restricted cytotoxic T lymphocytes induced in rats against syngeneic HTLV-I-infected cells. J Immunol. 1990; 144:4202-4211.
• [46]Miura S, Ohtani K, Numata N, Niki M, Ohbo K, Ina Y et al.. Molecular cloning and characterization of a novel glycoprotein, gp34, that is specifically induced by the human T-cell leukemia virus type I transactivator p40tax. Mol Cell Biol. 1991; 11:1313-1325.
• [47]Ootsuyama Y, Shimotohno K, Miwa M, Oroszlan S, Sugimura T. Myristylation of gag protein in human T-cell leukemia virus type-I and type-II. Jpn J Cancer Res. 1985; 76:1132-1135.
• [48]Tanaka R, Yoshida A, Murakami T, Baba E, Lichtenfeld J, Omori T et al.. Unique monoclonal antibody recognizing the third extracellular loop of CXCR4 induces lymphocyte agglutination and enhances human immunodeficiency virus type 1-mediated syncytium formation and productive infection. J Virol. 2001; 75:11534-11543.
• [49]Gunning P, Leavitt J, Muscat G, Ng SY, Kedes L. A human beta-actin expression vector system directs high-level accumulation of antisense transcripts. Proc Natl Acad Sci USA. 1987; 84:4831-4835.
• [50]Matsumoto K, Shibata H, Fujisawa JI, Inoue H, Hakura A, Tsukahara T et al.. Human T-cell leukemia virus type 1 Tax protein transforms rat fibroblasts via two distinct pathways. J Virol. 1997; 71:4445-4451.
• [51]Akagi T, Ono H, Nyunoya H, Shimotohno K. Characterization of peripheral blood T-lymphocytes transduced with HTLV-I Tax mutants with different trans-activating phenotypes. Oncogene. 1997; 14:2071-2078.
• [52]Hirai H, Suzuki T, Fujisawa J, Inoue J, Yoshida M. Tax protein of human T-cell leukemia virus type I binds to the ankyrin motifs of inhibitory factor kappa B and induces nuclear translocation of transcription factor NF-kappa B proteins for transcriptional activation. Proc Natl Acad Sci USA. 1994; 91:3584-3588.
• [53]Fujisawa J, Toita M, Yoshida M. A unique enhancer element for the trans activator (p40tax) of human T-cell leukemia virus type I that is distinct from cyclic AMP- and 12-O-tetradecanoylphorbol-13-acetate-responsive elements. J Virol. 1989; 63:3234-3239.
• [54]Kozlow EJ, Wilson GL, Fox CH, Kehrl JH. Subtractive cDNA cloning of a novel member of the Ig gene superfamily expressed at high levels in activated B lymphocytes. Blood. 1993; 81:454-461.
• [55]Mizuguchi M, Asao H, Hara T, Higuchi M, Fujii M, Nakamura M. Transcriptional activation of the interleukin-21 gene and its receptor gene by human T-cell leukemia virus type 1 Tax in human T-cells. J Biol Chem. 2009; 284:25501-25511.
• [56]Hirai H, Fujisawa J, Suzuki T, Ueda K, Muramatsu M, Tsuboi A et al.. Transcriptional activator Tax of HTLV-1 binds to the NF-kappa B precursor p105. Oncogene. 1992; 7:1737-1742.
• [57]Ohtani K, Iwanaga R, Arai M, Huang Y, Matsumura Y, Nakamura M. Cell type-specific E2F activation and cell cycle progression induced by the oncogene product Tax of human T-cell leukemia virus type I. J Biol Chem. 2000; 275:11154-11163.
• [58]Ohtani K, Nakamura M, Saito S, Noda T, Ito Y, Sugamura K et al.. Identification of two distinct elements in the long terminal repeat of HTLV-I responsible for maximum gene expression. EMBO J. 1987; 6:389-395.